Puberty blocker: drug companies’ shares fall after landmark transgender case
The companies behind controversial puberty blockers at the centre of a landmark transgender ruling have seen their share prices dip.
en staff
The firms, AbbVie Inc and Takeda, saw the value of their shares fall in the aftermath of the Kiera Bell case.
